Health
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Sobi North Americ
About this update from Swedish Orphan Biovitrum Ab
[{"type":"image","alt":"Sobi, Inc.","displaySize":"","headline":null,"caption":"Sobi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/860496ad964984ca29b78786bfce3044"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k7pxobviwy_rrIYlAznTpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/860496ad964984ca29b78786bfce3044","width":300,"height":82}},"lazy":false},{"type":"text","content":"NASP data highlight reduction in disease burden among people living with uncontrolled gout","length":90,"tagName":"p"},{"type":"text","content":"Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease","length":151,"tagName":"p"},{"type":"text","content":"Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome","length":189,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of data across its immunology portfolio highlighting the company’s continued leadership in addressing rare and underserved inflammatory conditions. A total of 15 scientific abstracts, including six oral presentations featuring new data from completed and ongoing studies of Nanoecapsulated Sirolimus plus Pegadricase (NASP, formerly SEL-212), Vonjo® (pacritinib), and Gamifant® (emapalumab-lzsg), are being presented at the annual American College of Rheumatology (ACR) Convergence 2025 meeting in Chicago, October 24-29, 2025. “Uncontrolled gout is a distinct and severe form of gout, marked by intense pain and an increased risk of mortali...